MedTrace Logo

A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study

NCT04800146 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 177

Last updated 2023-03-23

No results posted yet for this study

Summary

This is a single centre prospective observational study to assess the immune response to SARS-CoV-2 vaccines in cancer patients receiving active treatment or in follow-up at the IOSI and in non-cancer patients (age and gender matched).

Conditions

Interventions

PROCEDURE

Blood sample

Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination

Sponsors & Collaborators

  • Institute for Research in Biomedicine

    collaborator UNKNOWN

  • Ente Ospedaliero Cantonale, Bellinzona

    collaborator OTHER

  • Ilaria Colombo

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-25
Primary Completion
2023-03-21
Completion
2023-03-21

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04800146 on ClinicalTrials.gov